COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, ranging from asymptomatic infection to severe respiratory and systemic illness.
Retail pharmacy chains that expanded into clinical trials after COVID have since slowed or pulled back. CVS said it would exit by the end of 2024, Walmart shut its health clinics in 2024, and Walgreens has not commented formally on its business status.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Pfizer and Valneva said their investigational Lyme disease vaccine showed more than 70% efficacy in the Phase 3 VALOR trial with a favorable safety profile. The companies plan regulatory submissions despite the trial missing its primary statistical criterion due to fewer Lyme cases than expected.
Moderna will pay $2.25 billion to settle patent disputes with Arbutus Biopharma and Genevant Sciences over lipid nanoparticle technology used in its COVID-19 vaccine. The settlement removes uncertainty for Moderna's vaccine pipeline and sent the stock surging over 11%. The company expects to end 2026 with $4.5-$5 billion in cash and return to revenue growth by year-end.
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
The FDA agreed to review Moderna's mRNA-1010 seasonal flu vaccine after initially refusing to file the application, setting a decision date of August 5, 2026. If approved, it would be the first mRNA-based seasonal influenza vaccine on the market.
Moderna's seasonal influenza vaccine candidate mRNA-1010 receives FDA acceptance after initial refusal, with a PDUFA date set for August 5, 2026. The revised application proposes full approval for adults 50-64 and accelerated approval for those 65 and older.
Researchers at Stanford and Harvard are developing nasal spray vaccines offering broad protection against respiratory infections, with early animal and phase 1 human trials showing safety and potential efficacy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07221097 |
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses |
RECRUITING | |
| NCT07196306 |
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19 |
WITHDRAWN | PHASE2 |
| NCT06821139 |
Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority |
COMPLETED | |
| NCT06763887 |
Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population |
COMPLETED | |
| NCT06744660 |
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test |
RECRUITING | NA |
| NCT06692400 |
The Effects of Endotracheal Suctioning on Pain and Serum Markers |
RECRUITING | NA |
| NCT06652451 |
Covid-19 Data Analyses in Brazil |
COMPLETED | |
| NCT05137795 |
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 |
WITHDRAWN | PHASE3 |
| NCT04946162 |
The Use of Tadalafil in Confirmed COVID-19 Pneumonia. |
WITHDRAWN | PHASE4 |
| NCT04916561 |
Detection of Covid-19 in Tissue Samples of Orthopedic Origin |
COMPLETED |
